Edition:
United States

Eyenovia Inc (EYEN.OQ)

EYEN.OQ on NASDAQ Stock Exchange Capital Market

9.00USD
16 Feb 2018
Change (% chg)

$0.25 (+2.86%)
Prev Close
$8.75
Open
$8.95
Day's High
$9.15
Day's Low
$8.95
Volume
1,634
Avg. Vol
--
52-wk High
$10.60
52-wk Low
$8.51

Summary

Name Age Since Current Position

Fredric Eshelman

68 Chairman of the Board

Sean Ianchulev

2017 President, Chief Executive Officer

John Gandolfo

55 Chief Financial Officer

Luke Clauson

R & D, Engineering

Curt Labelle

2017 Director

Ernest Mario

78 Director

Biographies

Name Description

Fredric Eshelman

Dr. Fredric N. Eshelman is Chairman of the Board of the Company. Dr. Eshelman has more than 35 years of strategic development, executive, operational and financial leadership experience in the pharmaceutical and healthcare industries. Dr. Eshelman was the founder of Pharmaceutical Product Development, Inc. (PPD) and founding chairman of Furiex Pharmaceuticals, Inc. He is also the founder of Eshelman Ventures, LLC, an investment company focused on healthcare companies. Dr. Eshelman’s career has included executive positions at Glaxo, Inc. as well as various management positions at Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. He earned a B.S. in pharmacy from the University of North Carolina at Chapel Hill, received his Doctor of Pharmacy from the University of Cincinnati, and completed a residency at Cincinnati General Hospital.

Sean Ianchulev

Dr. Sean Ianchulev M.D is President, Chief Executive Officer of the Company. Dr. Ianchulev is a prolific inventor, innovator, physician-executive and public health expert with deep life-science and medical technology expertise. He has been at the forefront of medical products and technologies which have transformed the ophthalmic field and impacted medical care for thousands of patients. He is currently a Professor of Ophthalmology at the New York Eye and Ear Infirmary and sits on the Boards of Iantech Medical, Kurobe Pharmaceuticals and The American Society of Cataract and Refractive Surgery Foundation. Dr. Ianchulev spent five years at Genentech where headed the ophthalmology research group and directed the development and FDA approval of Lucentis, the most successful specialty biologic in the field of ophthalmology with more than $4B of annual sales. Dr. Ianchulev completed his MD at Harvard Medical School and his MPH, Health Policy, Finance, and Management at the Harvard School of Public Health.

John Gandolfo

Mr. John P. Gandolfo is Chief Financial Officer of the Company. John Gandolfo brings more than 30 years of experience as a finance executive of rapidly growing private and publicly held companies in the life sciences, healthcare and medical device areas. Prior to joining Eyenovia, John was the Chief Financial Officer of Xtant Medical – a global developer and manufacturer of biologics and implants for orthopedic and spine applications. Previously, he served as the Chief Financial Officer for Progenitor Cell Therapy, a leading manufacturer of stem cell therapies, and as the CFO of Power Medical Interventions, a publicly held developer and manufacturer of computerized surgical systems. He was also the CFO of several other public and private companies, namely Bioject Medical Technologies, Capital Access Network, Impath and Medical Resources.

Luke Clauson

Mr. Luke Clauson is an Executive Officer of the Company. He is responsible for R & D, Engineering. Mr. Luke Clauson started his engineering career at Cardica where he eventually directed product development for the core anastomotic business. In 2004, he founded Innovative Drive, a medical device focused engineering development company that has helped businesses of all sizes conceptualize and bring products to market. Since, Luke was a VP of R&D/OPS at Transcend Medical and more recently as a technology co-founder at IanTech, Inc.

Curt Labelle

Dr. Curt H. Labelle, M.D., MBA, is Director of the Company. Dr. LaBelle has been investing in and working with healthcare companies for over 16 years. He is the managing partner of the Global Health Investment Fund which invests in companies developing products for conditions that disproportionately affect the developing world. He has served as a Board member or observer for many successful companies, including KAI Pharmaceuticals (sold to Amgen), Sirion Therapeutics (sold to B&L and Alcon), Impulse Monitoring (sold to NuVasive), TransMolecular (sold to Morphotek), Estech (sold to Atricure), Coherex (sold to J&J), Exagen Diagnostics, SafeOp among others. Dr. Labelle obtained his MD from Columbia University’s College of Physicians and Surgeons, MBA from Columbia University Business School and Bachelors in Economics from Brigham Young University.

Ernest Mario

Dr. Ernest B. Mario, Ph.D., is Director of the Company. Dr. Mario has been a leader in the pharmaceutical space for XX years. Dr. Mario served as Chief Executive Officer and Chairman of Reliant Pharmaceuticals, Inc., a privately held pharmaceutical company that was acquired by GSK for approximately $1.6 billion in 2007. Dr. Mario served as Chief Executive Officer and Chairman of ALZA Corporation, a research-based pharmaceutical company, which was acquired by Johnson & Johnson for approximately $12 billion. He served as a trustee of Duke University from 1989 to 2007 and chaired the Duke University Health System board of trustees from its inception until 2007. Dr. Mario holds a BS in Pharmacy and Honorary Doctorate from Rutgers, The State University of New Jersey. He also earned a MS in Physical Sciences and PhD in Physical Science and Honorary Doctorate from University Of Rhode Island.

Basic Compensation

Options Compensation